My understanding is the route we have taken is slower but more prudent to check all the fda requirment before you start a registration trial ie those animals studies in AR have only just been finshed this year. Also the new MTD gives us a better shot but again they did not like the time wasted. As far as I could tell much centred around wanting this drug in registration trials yesterday not next year and management did not listen to them. You be the judge on their motives for selling.
- Forums
- ASX - By Stock
- KZA
- Ann: Kazia Annual Report
Ann: Kazia Annual Report, page-47
-
- There are more pages in this discussion • 100 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online